ABSTRACT

Objective: We sought to determine the rate of the K65R mutation in patients receiving tenofovir (TDF)-based antiretroviral treatment (ART) with subtype C HIV infection compared to reports on patients with subtype B HIV infection.

Design: Retrospective cohort study.

Methods:  All patients initiated on d4T+3TC or TDF+3TC plus a NNRTI at McCord Hospital in Durban, South Africa had their charts reviewed. All patients with virologic failure (VF), defined as a viral load (VL) > 1000 copies/mL after 5 months of a first ART regimen, had genotypic resistance testing performed prospectively using a validated in-house assay. Important resistance mutations were selected based upon published mutations in subtype B virus in the Stanford HIV Drug Resistance (DR) Database.

Results: A total of 585 patients were initiated on TDF-containing first-line ART from August 3, 2010 to March 17, 2011. Thirty-five (6.0%) of these patients had VF and 23/33 (69.7%) of the VF patients had the K65R mutation. The median (IQR) for the baseline CD4 count was 105 cells/uL (49-209) and VL at VF was 47,571 copies/mL (20,708-202,000). During the same time period, 53 patients were initiated on d4T-containing regimens. Two (3.8%) of these patients had VF and 1 of the VF patients had the K65R mutation.

Conclusions: Preliminary data show very high rates (>65%) of K65R for patients failing TDF-based first-line regimens at McCord with few additional NRTI mutations compared to patients with subtype B. These rates may reflect faster *in vivo* selection, longer time on a failing regimen, or transmitted DR.

Word count: 248

**Title: High rate of K65R for ART naïve patients with subtype C HIV infection failing a TDF-containing first-line regimen in South Africa**

Running Headline: K65R after TDF-based first-line ART in Subtype C

Total words: 1655 (max 1800)

Authors:

Henry Sunpath

McCord Hospital, Durban, South Africa

[corresponding author email: henrysunpath@yebo.co.za and current address:

45 McCord Road, Overport, South Africa]

[Study design and implementation, Manuscript preparation and data collection]

Baohua Wu

Rollins School of Public Health, Emory University, Atlanta, Georgia

[Statistical analysis]

Michelle Gordon

Nelson Mandela School of Medicine, Durban, South Africa

[Drug resistance testing and study design]

Jane Hampton

McCord Hospital, Durban, South Africa

[Study design and implementation, Data collection]

Brent Johnson

Rollins School of Public Health, Emory University, Atlanta, Georgia

[Statistical analysis]

Roma Maharaj   
McCord Hospital, Durban, South Africa

[Study implementation, Data collection, Statistical analysis]

Yunus Moosa

Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa  
[Study design and implementation and critical review of manuscript]

Claudia Ordonez

McCord Hospital, Durban, South Africa

[Study design and implementation and critical review of manuscript]

Daniel R. Kuritzkes1

Section of Retroviral Therapeutics, Brigham and Women’s Hospital, Boston, MA

[Study design and critical review of manuscript]

Vincent C. Marconi

Emory University School of Medicine, Atlanta, Georgia

Rollins School of Public Health, Emory University, Atlanta, Georgia

[Study design, Manuscript preparation and data collection]

SARCS Team Group Authors [Contributed to initial study design, Manuscript preparation and data collection]

[Helga Holst, Sifiso Shange, Melisha Pertab (McCord Hospital, Sinikithemba Clinic, Durban, South Africa)]

Potential conflicts of interest

1. D.R.K. is a consultant to, or has received research funding from Abbott, Boehringer-

Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck and Roche.

**Key words:** first-line antiretroviral therapy, virologic failure, HIV-1 drug resistance, K65R, tenofovir, South Africa, subtype C virus.

INTRODUCTION:

Tenofovir (TDF) has been part of first-line antiretroviral therapy (ART) for most developed countries since 2001. Because of potency, durability, tolerability, favorable pharmacokinetics and drug interaction profile, TDF quickly emerged as one of the two most commonly prescribed NRTI’s for antiretroviral (ARV) naïve subjects.[[1](#_ENREF_1)] In areas endemic for hepatitis B virus (HBV), TDF has the added benefit of possessing activity against HBV. In April, 2010 TDF was introduced as part of first-line ART in the South African national treatment plan, replacing the more toxic ARV, stavudine (d4T).[[2](#_ENREF_2)] To date, there are no published reports on the effectiveness of TDF as part of first-line ART in this setting.

The reverse transcriptase (RT) mutation K65R results in a four-fold decrease in TDF susceptibility and is selected by TDF, didanosine (ddI), d4T and abacavir (ABC). The K65R mutation has been reported in 7-15% of patients failing d4T-, ddI- or zidovudine- (AZT) containing first or second-line ART in South Africa, where subtype C accounts for most HIV-1 infections, compared to 2-5% of patients in parts of the world where infection with subtype B dominates.[[3-10](#_ENREF_3)] *In vitro* studies provide some evidence for more rapid selection of K65R in subtype C virus.[[11-13](#_ENREF_11)] We previously reported the virologic effectiveness and prevalence of drug resistance (DR) mutations after initiating first-line ART in South Africa.[[14](#_ENREF_14)] In this study, we sought to determine the virologic outcomes and rate of K65R emergence amongst patients with virologic failure after initiating TDF-containing ART as first-line treatment in a clinic in Durban, South Africa.

METHODS:

A retrospective analysis of HIV-1 DR was conducted at McCord Hospital, which has been treating patients with ART since 2002. All patients initiated on d4T+3TC or TDF+3TC plus a NNRTI from August 3, 2010 to March 17, 2011 were included in the analysis. Virologic failure (VF) was defined as a VL > 1000 copies/mL after 5 months of a first ART regimen. Genotypic resistance testing was performed prospectively as part of a larger research study on all patients with VF using a validated in-house assay. This study was approved by the respective ethics committees at McCord Hospital and by the institutional review board at Emory University in Atlanta, Georgia. All VF patients provided written informed consent for study participation. Important resistance mutations were selected based upon the published mutations on subtype B virus in the Stanford HIV DR Database. The prevalence of drug-resistant virus in the samples tested was reported with 95% CIs, calculated based upon normal approximation of binomial distribution. RT and protease resistance mutations were also reported.

Data collected at baseline included age, gender, prior AIDS-defining illnesses, ART treatment history, CD4 cell count and plasma HIV-1 RNA level at time of regimen failure. Analyses were performed using SAS software, version 9.3 (SAS Institute). All tests of statistical significance were 2-sided; associations with P < 0.05 were considered to be statistically significant. Continuous variables were compared using the Wilcoxon rank-sum test; categorical variables were compared using the χ2 test or Fisher’s exact test. Univariate and multivariate logistic regression were used to identify variables associated with the presence of K65R. Variables known to be associated with study outcomes, as well as independent variables exhibiting an association with study outcomes in the bivariate analysis at P < 0.1 or odds ratios of > 1.5 (or < 0.6), were advanced into the multivariate analyses.

RESULTS:

Of 585 patients initiated on TDF-containing first-line ART 35 (6.0%) experienced VF. Baseline characteristics of these patients are presented in Table 1. The median age (range) was 37.3 yrs (31.2-45.0), 45.7% of the patients were women, 88.6% were on an efavirenz, and the median duration of TDF and ART was 5.3 (5.0-6.1) and 5.7 (5.2-15.1) months, respectively. The median number of prior AIDS-defining illnesses was 1 (1.0-2.0), with tuberculosis being the most common (74.3%). The median (IQR) CD4 count at study entry was 105 cells/uL (49-209); median VL at study entry (VF) was 47,571 copies/mL (20,708-202,000). Two patients had virus that could not be amplified for resistance genotyping. All isolates were subtype C. Twenty-three (69.7%) of the 33 patients with VF and amplifiable virus had the K65R mutation. Additional RT mutations found with the K65R included Y115F (7 patients), L74V (2), M184V (9), T69D/N (3), K70T (1), V179D (5), Y181C (7), V106M (18), Y188C (5), G190A/E (9), V108I (2), A98G (2), K103N (8).

In contrast, 53 patients initiated a d4T-containing regimen during the same time period. Two (3.8%) of these patients had VF and one had the K65R mutation. Additional RT mutations with the K65R included K103N and V106M.. Median duration of ART appeared different between the two groups but no statistial test is reported due to low sample size in the group initiating a d4T-containing regimen. For those commencing d4T the median duration of ART was 13.7 (5.3-22.2) months compared to 5.7 (5.2-15.1) months for TDF. Ten (28.6%) of the 35 TDF patients had prior d4T and had been previously switched to TDF for toxicity (not virologic failure) after a median of 24.8 months (15.1-30.1) on d4T. One of these patients could not be genotyped. Of the remaining 9 patients, 4 (44.4%) had the K65R mutation. Therefore if these 9 patients were excluded from the 33 total patients with amplifiable virus on TDF, then 19 (79.2%) had the K65R mutation.

The following factors were evaluated, using regression analysis, to determine their association with K65R amongst patients failing a TDF-containing first-line ART: age, gender, regimen, CD4 count, viral load, duration of ART and prior AIDS-defining illnesses. No associations were found in univariate regression and therefore multivariate models were not constructed.

DISCUSSION:

ART has been shown to be effective in the treatment of HIV-1 infection, regardless of the viral subtype. However, specific DR mutations can emerge at different rates and the prevalence of some DR mutations differs depending upon the subtype.[[6](#ENREF_6)][[15](#_ENREF_15)] An understanding of DR patterns among non-B subtype infections may help to optimize the selection of first-line ART in order to limit the emergence of DR. Resistance pathways, which could compromise the use of second-line ARVs through cross-resistance, also vary among different subtypes.[[16](#_ENREF_16)] This concern may be increased in developing countries where formularies are limited.[[4](#ENREF_4)]

During the initial ART rollout at McCord Hospital, the K65R mutation in patients failing first-line therapy for at least six months was reported in only three patients out of a total of 147 (2.6%).[[5](#ENREF_5)] Although some of these patients had prior suboptimal ART, most were naïve and failing on a d4T-, ddI- or AZT-based regimen. In that study, 97.4% of patients had subtype C virus. Of concern, HIV-1 from approximately 20% of patients in areas in which subtype C is endemic carries the K65R mutation, the K70E mutation, or both after experiencing VF of a d4T- or ddI-based ART regimen.[[4](#ENREF_4)] K65R was also detected in 7 to 15% of patients in South Africa who did not have a response to first- or second-line regimens with d4T, ddI, or AZT as the nucleoside backbone.[[2](#ENREF_2)] Some of the differences in these rates of acquisition of K65R or thymidine analog mutations (TAMs) are doubtless due to treatment regimens and disease stage, as well as limited access to viral-load testing in many developing countries.

In this analysis, the findings of relatively fewer M184V mutations and absence of TAMs provides some evidence of the antagonism that exists between these mutations and K65R. Although the M184V mutation may have emerged early, variants with this mutation would have been overcome by the more fit K65R variants which likely emerged later. Recent data suggest that increased rates of K65R acquisition in subtype C may be due to the nature of the subtype C RNA template. In particular, RT of subtype C viruses may be especially prone to pausing events at codon 65 due to a poly-adenine region that allows for misalignment, misincorporation, strand transfer, insertions, deletions and recombinations, thereby facilitating the acquisition of K65R during reverse transcription.[[3](#ENREF_3)]Ultrasensitive pyrosequencing methods have also shown that K65R can be selectively transmitted as minority species to some populations that have not yet received antiretroviral therapy.[[7](#ENREF_7)] Transmission of these variants could jeopardize not only first-line ART but also pre- and post-exposure prophylaxis strategies containing TDF.[[8](#ENREF_8), [9](#ENREF_9)]

There are a few limitations of this study that should be noted. First, there may be a selection bias associated with the study population as is common in retrospective or cross-sectional studies. Patients who were lost to follow up, died or changed service providers prior to study entry would not have been included in this analysis. Additionally, the relatively small sample size does not allow for effective comparisons to be made with the concurrent d4T group and could be an explanation for why risk factors for K65R emergence could not be determined. However, it is unlikely that a larger sample size would significantly alter the prevalence of the K65R mutation for patients receiving TDF and comparisons can be made with the historical reports of virologic failure and K65R for patients receiving d4T-containing ART in this same setting.

K65R is uncommon among patients with subtype B who have received either tenofovir or a combination of tenofovir and emtricitabine as part of triple antiretroviral-drug therapy.[[2](#ENREF_2)] The data reported here show very high rates (>65%) of K65R for patients failing TDF-based first-line regimens at McCord with few additional NRTI mutations. These rates may reflect faster in vitro selection, longer time on a failing regimen, or transmitted DR. Larger numbers of patients and longer follow-up are required to determine whether the emergence of K65R in subtype C is consistent and clinically relevant in this setting. Although risk factors were not identified in this analysis, larger studies may reveal which patients could be at risk for developing K65R. It is an urgent global priority to optimize treatment strategies for HIV infection, regardless of geographic locale. Moreover, this study provides additional evidence that the provision of VL monitoring and genotypic resistance testing, both before and after ART, needs to be expanded to include all developing countries.[[17](#_ENREF_17), [18](#_ENREF_18)]

Acknowledgements

We would like to express our deepest admiration and appreciation for the work of the Sinikithemba Clinic at McCord Hospital in Durban, South Africa. The support for clinical research to improve patient care on the part of the counselors, medical records staff, nurses, and medical officers has been essential. Kristy Nixon provided vital assistance in the data collection.

Financial support

Grant support from Emory University Center for AIDS Research (CFAR) (P30 AI050409) and the Emory School of Medicine Division of Infectious Diseases, NIH (P30 AI60354 to Harvard University CFAR and K24 RR16482 to D.R.K.), Harvard University Program on AIDS, CDC Cooperative Agreement (U62/CCU123541-01), Elizabeth Glaser Pediatric AIDS Foundation as part of Project HEART, and the Gilead Foundation.

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: Department of Health and Human Services.; October 14, 2011. pp. 1-167.

2. The South African Antiretroviral Treatment Guidelines 2010. In: Department of Health Republic of South Africa and South African National AIDS Council; 2010. pp. 3.

3. McColl DJ, Chappey C, Parkin NT, Miller MD. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. *Antivir Ther* 2008,**13**:189-197.

4. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? *Int J Clin Pract* 2008,**62**:1285-1293.

5. Miller MD. K65R, TAMs and tenofovir. *AIDS Rev* 2004,**6**:22-33.

6. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C*, et al.* Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis* 2011,**204**:1191-1201.

7. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. *J Acquir Immune Defic Syndr* 2003,**33**:15-21.

8. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. *HIV Med* 2006,**7**:442-450.

9. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. *J Acquir Immune Defic Syndr* 2004,**37**:1340-1350.

10. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C*, et al.* Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. *N Engl J Med* 2003,**349**:2293-2303.

11. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. *HIV therapy* 2009,**3**:583-594.

12. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG*, et al.* Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. *Journal of virology* 2009,**83**:2029-2033.

13. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. *The New England journal of medicine* 2011,**365**:637-646.

14. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J*, et al.* Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. *Clin Infect Dis* 2008,**46**:1589-1597.

15. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. *Aids* 2008,**22**:2210-2212.

16. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). *J Int AIDS Soc* 2009,**12**:11.

17. van Zyl GU, Preiser W, Potschka S, Lundershausen AT, Haubrich R, Smith D. Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting. *Clin Infect Dis* 2011,**52**:264-270.

18. Rosen S, Long L, Sanne I, Stevens WS, Fox MP. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. *J Int AIDS Soc* 2011,**14**:24.

**Table 1. Baseline characteristics of patients with virologic failure during first-line ART with and without tenofovir.**

| *Characteristic* |  | *All patients (n=37)* | *TDF-containing (n=35)* | *No TDF use (n=2)* |
| --- | --- | --- | --- | --- |
| Age, Mean ± SEM [IQR] |  | 37.3 [31.2 – 45.0] | 37.3 [31.2 – 45.0] | 37.1 [28.1 – 46.1] |
| Women (%) |  | 18/37 (48.6%) | 16/35 (45.7%) | 2/2 (100.0%) |
| EFV (%) |  | 33/37 (89.2%) | 31/35 (88.6%) | 2/2 (100.0%) |
| Median duration of ART (months) [IQR] by TDF/D4T |  | 5.3 [5.0 – 6.1] | 5.3 [5.0 – 6.1] | 7.1 [4.7 – 9.5] |
| Median duration of ART (months) [IQR] |  | 5.7 [5.2 – 15.1] | 5.7 [5.2 – 15.1] | 13.7 [5.3 – 22.2] |
| Median CD4 count at virologic failure (cells/ul) [IQR] |  | 107.0 [49.0 – 209.0] | 105.0 [49.0 – 209.0] | 173.0 [173.0 – 173.0] |
| CD4 cell count category (%) | 0-49 cells/ul | 8/37 (21.6%) | 8/35 (22.9%) | 0/2 (0.0%) |
|  | 50-99 cells/ul | 4/37 (10.8%) | 4/35 (11.4%) | 0/2 (0.0%) |
|  | 100-199 cells/ul | 8/37 (21.6%) | 7/35 (20.0%) | 1/2 (50.0%) |
|  | 200-349 cells/ul | 5/37 (13.5%) | 5/35 (14.3%) | 0/2 (0.0%) |
|  | >350 cells/ul | 2/37 (5.4%) | 2/35 (5.7%) | 0/2 (0.0%) |
| Median plasma viral load at virologic failure (copies/ml) [IQR] |  | 45,817 [19212 – 194,000] | 47,571 [20,708 – 202,000] | 23,173 [2365 – 43,981] |
| Viral load category (copies/ml) (%) | 400-4,999 | 5/37 (13.5%) | 4/35 (11.4%) | 1/2 (50.0%) |
|  | 5,000-29,999 | 7/37 (18.9%) | 7/35 (20.0%) | 0/2 (0.0%) |
|  | 30,000-99,999 | 13/37 (35.1%) | 12/35 (34.3%) | 1/2 (50.0%) |
|  | > 100,000 | 11/37 (29.7%) | 11/35 (31.4%) | 0/2 (0.0%) |
| Prior AIDS-defining illness |  | 1.0 [1.0 - 2.0] | 1.0 [1.0 - 2.0] | 1.0 [1.0 – 1.0] |
| TB |  | 28/37 (75.7%) | 26/35 (74.3%) | 2/2 (100.0%) |
| KS |  | 1/37 (2.7%) | 1/35 (2.9%) | 0/2 (0.0%) |
| Toxoplasmosis |  | 2/37 (5.4%) | 2/35 (5.7%) | 0/2 (0.0%) |
| Cryptococcal Meningitis |  | 1/37 (2.7%) | 1/35 (2.9%) | 0/2 (0.0%) |

TDF – tenofovir, EFV – efavirenz, ART – antiretroviral therapy, TB – tuberculosis, HSV – herpes simplex virus, KS – Kaposi’s Sarcoma, IQR – interquartile range; For a sample of size 2, the median and IQR are the mean and range, respectively; 1 of 2 patients in the d4T group is missing CD4 cell count.

**Table 2. Factors associated with K65R amongst patients failing a tenofovir-based first-line ART.**

| *Factor* |  | *Odds Ratio* | *95% CI* | *p value* |
| --- | --- | --- | --- | --- |
| Age |  | 0.93 | [0.84-1.03] | 0.16 |
| Gender | Male vs Female | 2.93 | [0.50-22.15] | 0.31 |
| Regimen(EFV) | EFV Yes vs No | 0.75 | [0.01-10.89] | 1.00 |
| CD4 Count | 50-99 cells/ul vs 0-49 cells/ul | 1.00 | [0.04-78.43] | 1.00 |
|  | 100-199 cells/ul vs 0-49 cells/ul | 0.84 | [0.04-15.78] | 1.00 |
|  | 200-349 cells/ul vs 0-49 cells/ul | 1.00 | [0.04-78.43] | 1.00 |
|  | >350 cells/ul vs 0-49 cells/ul | 0.50 | [0.00-9.50] | 0.67 |
| Viral Load | 5,000-29,999 vs 400-4,999 | 0.74 | [0.00-7.20] | 0.83 |
|  | 30,000-99,999 vs 400-4,999 | 0.98 | [0.00-9.06] | 0.99 |
|  | >100,000 vs 400-4,999 | 2.27 | [0.00-23.15] | 1.00 |
| Duration of ART |  | 1.01 | [0.97-1.05] | 0.58 |
| Prior AIDS-defining illness |  | 1.00 | [0.28-3.54] | 1.00 |

Statistial tests from exact logistic regression; ART – antiretroviral therapy